Geftinat is a new generation drug used in the treatment of non-small cell lung cancer. Geftinat is a generic (analogous) preparation of Iress, which has a high anticancer activity. The original tool is designed and manufactured in the US. Geftinat and Iressa have the same active ingredient - Gefitinib, therefore they have the same useful properties. An important difference between these two drugs is the cost. Prices for generics are several times lower, so they are more affordable. Indication for use in non-small cell lung cancer, in a locally advanced form or with metastases. As the first line of chemotherapy is used in the presence of the receptors of EGF (epidermal growth factor) mutations of the tyrosine kinase domain.